

Paige is Transforming Cancer Diagnostics

At Paige, we believe that better technology is the answer to better patient care.

Our mission is to develop and deliver a new generation of diagnostic and biomarker Al applications, empowering pathologists and transforming oncology.

Harnessing the Incredible Power of Tissue-Based Al

Offering a cloud-based SaaS platform, groundbreaking diagnostic and biomarker AI applications, access to third-party AI, and seamless custom AI development and deployment, Paige delivers:



A streamlined end-to-end digital pathology workflow



Trusted clinical-grade Al designed to support pathologists



Enhanced efficiency and diagnostic confidence



The ability to identify and validate new predictive or prognostic biomarkers from Paige or external data




Rapidly developed Al-powered algorithms to support clinical trial testing and companion diagnostics



Seamless launch of existing or co-developed AI algorithms at sites around the world









Access to highly specialized, diverse global data has provided Paige with one of the largest data sets used to develop AI software. This enabled us to build the first-ever FDA approved AI pathology product, Paige Prostate Detect, as well as best-in-class detection algorithms for uncovering cancer features from H&E-stained whole slide images alone.



Paige's Al works across global institutions, spanning pre-analytical variations and staining techniques, offering robust performance without the need for tuning or recalibration.



Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare, Paige is uniquely positioned to transform the field of pathology.

Having acquired the first-ever FDA clearance for a clinical AI application in pathology, Paige has cleared the highest bar for quality, and this provides us with confidence as we introduce it into live patient reporting.

PAUL VAN DIEST, M.D., PH.D., Professor and Head of Pathology at UMC Utrecht